Iovance Biotherapeutics, Inc. (IOVA) stock
Close on Nov 17, 2026Market cap $3.41BP/E –Yield –
Earnings
Iovance Biotherapeutics's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Quarterly results
Revenue and earnings per share from each of Iovance Biotherapeutics's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Source |
|---|---|---|---|---|---|
| Q4 FY2026ended Dec 31, 2026 | Feb 23, 2027Expected | – | – | – | – |
| Q3 FY2026ended Sep 30, 2026 | Nov 5, 2026before the open | $121.47M | +80.1% | -$0.05 | Release |
| Q2 FY2026ended Jun 30, 2026 | Aug 6, 2026before the open | $99.31M | – | -$0.11 | Release |
| Q1 FY2026ended Mar 31, 2026 | May 7, 2026before the open | – | – | – | Release |
| Q4 FY2025ended Dec 31, 2025 | Feb 24, 2026before the open | $86.71M | +17.7% | -$0.18 | Release |
| Q3 FY2025ended Sep 30, 2025 | Nov 6, 2025before the open | $67.46M | – | -$0.25 | Release |
| Q2 FY2025ended Jun 30, 2025 | Aug 7, 2025after the close | – | – | – | Release |
| Q1 FY2025ended Mar 31, 2025 | May 8, 2025after the close | – | – | – | Release |
| Q4 FY2024ended Dec 31, 2024 | Feb 27, 2025after the close | $73.70M | +14640.0% | -$0.26 | Release |
| Q3 FY2024ended Sep 30, 2024 | Nov 7, 2024after the close | – | – | – | Release |
| Q2 FY2024ended Jun 30, 2024 | Aug 8, 2024after the close | $31.10M | +12967.2% | -$0.34 | Release |
| Q1 FY2024ended Mar 31, 2024 | May 9, 2024after the close | $700.00K | – | -$0.42 | Release |
| Q4 FY2023ended Dec 31, 2023 | Feb 28, 2024after the close | $500.00K | – | -$0.45 | Release |
| Q3 FY2023ended Sep 30, 2023 | Nov 7, 2023after the close | $500.00K | – | -$0.46 | Release |
| Q2 FY2023ended Jun 30, 2023 | Aug 8, 2023after the close | $238.00K | – | -$0.47 | Release |
| Q1 FY2023ended Mar 31, 2023 | May 9, 2023after the close | – | – | -$0.50 | Release |
| Q4 FY2022ended Dec 31, 2022 | Feb 28, 2023after the close | – | – | -$0.64 | Release |
| Q3 FY2022ended Sep 30, 2022 | Nov 3, 2022after the close | – | – | -$0.63 | Release |
| Q2 FY2022ended Jun 30, 2022 | Aug 4, 2022after the close | – | – | -$0.63 | Release |
| Q1 FY2022ended Mar 31, 2022 | May 5, 2022after the close | – | – | -$0.58 | Release |
| Q4 FY2021ended Dec 31, 2021 | Feb 24, 2022after the close | – | – | -$0.63 | Release |
| Q3 FY2021ended Sep 30, 2021 | Nov 4, 2021after the close | – | – | -$0.55 | Release |
| Q2 FY2021ended Jun 30, 2021 | Aug 5, 2021after the close | – | – | – | Filing |
| Q1 FY2021ended Mar 31, 2021 | May 6, 2021after the close | – | – | – | Filing |
| Q4 FY2020ended Dec 31, 2020 | Feb 25, 2021after the close | – | – | – | Filing |
| Q3 FY2020ended Sep 30, 2020 | Nov 5, 2020after the close | – | – | – | Filing |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Current guidance
Iovance Biotherapeutics's latest outlook for periods it has not reported yet, compared with what it said before
| Metric | Period | Guidance | Before | Change | Given |
|---|---|---|---|---|---|
| total product revenue | FY2026 | $410.00M – $420.00M | – | New | Nov 5, 2026 |
| total revenue guidance | FY2026 | $350.00M – $370.00M | $350.00M – $370.00M | Reaffirmed | Aug 6, 2026 |
Guidance vs results
The last range Iovance Biotherapeutics gave before each report, against the figure it then reported. Full years add up the four quarters.
| Period | Metric | Guidance | Actual | Result |
|---|---|---|---|---|
| Q2 FY2026 | Revenue | $86.00M – $88.00M | $99.31M | Above range |
Guidance history
Every forecast Iovance Biotherapeutics put in an earnings release, newest first
| Given | Metric | Period | Guidance | Change |
|---|---|---|---|---|
| Nov 5, 2026 | total product revenue | FY2026 | $410.00M – $420.00M | New |
| Aug 6, 2026 | total revenue guidance | FY2026 | $350.00M – $370.00M | Reaffirmed |
| May 7, 2026 | Total product revenue | FY2026 | $350.00M – $370.00M | New |
| May 7, 2026 | Total product revenue | Q2 FY2026 | $86.00M – $88.00M | New |
| May 7, 2026 | U.S. Amtagvi revenue | Q2 FY2026 | $79.00M – $81.00M | Lowered |
| Nov 6, 2025 | r evenue | FY2025 | $250.00M – $300.00M | New |
| Feb 27, 2025 | total product revenue | FY2025 | $450.00M – $475.00M | Reaffirmed |
| Aug 8, 2024 | Total product revenue | Q3 FY2024 | $53.00M – $55.00M | New |
| Aug 8, 2024 | Total product revenue | FY2024 | $160.00M – $165.00M | New |
| Aug 8, 2024 | total product revenue | FY2025 | $450.00M – $475.00M | New |
Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.
Press releases
Releases Iovance Biotherapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- News
- Results
- News
- News
- News
- News
- Results
- News
- News
- Results
- Results
- Results
- News
- Results
- News
See a number that looks wrong?